SLS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States...

Stats
Tagesvolumen	3.30M
Durchschnittsvolumen	1.45M
Marktkapitalisierung	68.08M
EPS	$0 ( 2024-03-28 )
Nächstes Ertragsdatum	( $-0.210 ) 2024-05-09
Last Dividend	$0.420 ( 2010-12-09 )
Next Dividend	$0 ( N/A )
P/E	-0.900
ATR14	$0.00800 (0.66%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Stergiou Angelos M.	Buy	159 000	Common Stock
2024-01-22	Stergiou Angelos M.	Buy	238 500	Stock Option (Right to Buy)
2024-01-22	Scheinberg David A	Buy	6 000	Common Stock
2024-01-22	Scheinberg David A	Buy	10 000	Stock Option (Right to Buy)
2024-01-22	Wood Barbara A	Buy	35 000	Common Stock

INSIDER POWER
95.64
Last 98 transactions
Buy: 3 194 450 \| Sell: 76 679

Volumen Korrelation

Lang: -0.13 (neutral)

Kurz: -0.86 (strong negative)

Signal:(56.234) Neutral

Sellas Life Sciences Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sellas Life Sciences Korrelation - Währung/Rohstoff

0.00
( neutral )

0.09
( neutral )

0.00
( neutral )

0.38
( neutral )

0.20
( neutral )

Sellas Life Sciences Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-1.340

FY	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-1.340

FY	2022
Umsatz:	$1.00M
Bruttogewinn:	$900 000 (90.00 %)
EPS:	$-2.10

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$-200 000 (0.00 %)
EPS:	$-2.60

Financial Reports:

No articles found.

Sellas Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sellas Life Sciences Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.150	2010-09-09
Last Dividend	$0.420	2010-12-09
Next Dividend	$0	N/A
Payout Date	2010-12-20
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.570	--
Avg. Dividend % Per Year	0.00%	--
Score	1.52	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-08)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0.570	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-5.80	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-23.94	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.231	0.800	-3.85	-3.08	[1 - 3]
quickRatioTTM	0.191	0.800	-3.58	-2.86	[0.8 - 2.5]
cashRatioTTM	0.191	1.500	-0.0473	-0.0710	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	154.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
freeCashFlowPerShareTTM	-1.242	2.00	-0.621	-1.242	[0 - 20]
debtEquityRatioTTM	-0.114	-1.500	-0.454	0.682	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-34.67	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.91

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.262	1.000	-0.229	0	[1 - 100]
returnOnEquityTTM	-23.94	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.242	2.00	-0.414	-1.242	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.978	2.00	-0.326	-0.652	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0245	1.500	-3.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.945

Sellas Life Sciences

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.